T-cell Engager vs Stem Cell Transplant for Multiple Myeloma
(FASTER Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).
Who Is on the Research Team?
Henning Schade, MD
Principal Investigator
Colorado Blood Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults with newly diagnosed multiple myeloma who've had prior therapy and responded partially. They must have measurable disease, be fit (ECOG 0-1), able to undergo stem cell transplant, and not need recent blood transfusions. It's not suitable for those outside these criteria or ineligible by institutional policy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Consolidation
Participants receive either elranatamab and daratumumab or undergo ASCT followed by lenalidomide and daratumumab
Maintenance 1
Participants receive maintenance treatment with either elranatamab and daratumumab or lenalidomide and daratumumab
Maintenance 2
Participants with MRD negativity continue with monotherapy maintenance treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Autologous Stem Cell Transplantation
- Daratumumab
- Elranatamab
- Lenalidomide
Find a Clinic Near You
Who Is Running the Clinical Trial?
SCRI Development Innovations, LLC
Lead Sponsor
coMMit, Myeloma Trials, Innovated
Collaborator
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University